Duvelisib
Duvelisib is a targeted cancer medication that works by inhibiting specific forms of the PI3K enzyme (PI3K-δ and PI3K-γ) that are important for the growth and survival of malignant B-cells. It is primarily used to treat certain blood cancers affecting B-cells, including chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). By blocking these signaling pathways, duvelisib helps control the proliferation of cancer cells and may induce their death.
Duvelisib is a PI3K inhibitor used to treat B-cell cancers like CLL and SLL by blocking key signaling pathways that cancer cells need to grow and survive.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- L01EM04
- RxNorm
- 2058509
- Generic
- Duvelisib
- Class
- atc-l01
- Brands
- Copiktra
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- capsule
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Duvelisib is indicated for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). It may also be used for follicular lymphoma in patients who have received at least two prior systemic therapies.
Duvelisib inhibits PI3K enzymes, specifically the δ and γ isoforms, which are expressed in normal and malignant B-cells. By blocking these enzymes, it disrupts critical signaling pathways that promote cancer cell growth, survival, and proliferation, ultimately reducing tumor cell viability.
Duvelisib carries warnings for serious adverse events including infections, diarrhea, colitis, hepatotoxicity, and pneumonitis. Patients should be monitored for these complications during treatment. The medication may increase the risk of skin reactions and should be dose-reduced or discontinued if severe toxicity occurs. It is typically administered orally and requires regular laboratory monitoring.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy